Loading...
Although ACE inhibitors may prevent nephropathy and poor cardiovascular outcomes in specific subgroups of diabetic patients, the benefit for the broader group of diabetics at high risk for cardiovascular and renal disease has not been established. In the Heart Outcomes Prevention Evaluation (HOPE) study and the MIcroalbuminuria, Cardiovascular, and Renal Outcomes (MICRO) HOPE substudy, researchers randomly assigned 3577 diabetics with previous cardiovascular events or at least 1 other cardiovascular risk factor to 10 mg ramipril daily or placebo.
Ramipril reduced the combined primary endpoint of MI, stroke, or cardiovascular death by 25 percent -- a statistic that remained significant even after adjusting for the drug's reduction of systolic…